CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6032 result(s)

Denosumab (Drug Plan Submission) (Xgeva)

Last Updated: September 7, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: Denosumab (Drug Plan Submission)
Indications: Prevention of skeletal-related events due to bone metastases from breast cancer

  • Brand Name: Xgeva
  • Manufacturer: Amgen Canada Inc.
  • Project Number: SR0433-000
  • Project Status: Complete
  • Submission Type: New

ticagrelor (Brilinta)

Last Updated: October 10, 2018
Result type: Reports
Product Line: Common Drug Review
Generic Name: ticagrelor
Indications: Prevention of atherothrombotic events with history of myocardial infarction

  • Brand Name: Brilinta
  • Manufacturer: AstraZeneca Canada Inc
  • Project Number: SR0474-000
  • Project Status: Complete
  • Submission Type: New Indication

Secukinumab (Cosentyx)

Last Updated: January 21, 2016
Result type: Reports
Product Line: Common Drug Review
Generic Name: Secukinumab
Indications: Arthritis, psoriatic

  • Brand Name: Cosentyx
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0476-000
  • Project Status: Complete
  • Submission Type: New